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Efficient transduction of primary hematopoietic cell types by oncoretroviral vectors and lentiviral vectors with a variety of different envelope
pseudotypes has proven to be difficult. We recently developed a lentiviral vector based upon a modified Sindbis virus envelope that allows
targeted transduction via antibody recognition to specific cells in unfractionated cell populations. However, similar to other envelope pseudotypes,
the utility of this vector for some primary hematopoietic cells was limited by low transduction efficiencies. Here, we report that transient treatment
of cells with low pH culture medium immediately following infection results in marked enhancements in transduction efficiency for primary
hematopoietic cells. In combination with antibody directed targeting, this simple technique expands the utility of targeting transduction to specific
cells in mixed populations of primary cells.
© 2006 Elsevier Inc. All rights reserved.Keywords: Lentiviral vector; Targeting vector; Sindbis envelope; Low pH treatmentIntroduction
Pseudotyping of retrovirus vectors by substitution of the
native envelope protein with one that uses different cell surface
receptors is commonly used as a means to alter gene
transduction efficiency and host cell tropism (Lewis et al.,
2001; Kobinger et al., 2001; Beyer et al., 2002; Liu et al., 2004;
Kahl et al., 2004; Watson et al., 2002). Envelope proteins of
vesicular stomatitis virus (VSV-G) and retroviruses, such as
amphotrophic MLV, RD114 and GALV, have been used for
pseudotyping retrovirus vectors (Mochizuki et al., 1998;
Naldini et al., 1996; Burns et al., 1993; Sandrin et al., 2002;
Lusso et al., 1990). Although the receptors for these envelope
proteins are expressed ubiquitously allowing infection of
multiple cell types, certain types of cells express these receptors⁎ Corresponding author.
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doi:10.1016/j.virol.2006.07.015poorly resulting in inefficient gene transduction (Unutmaz et al.,
1999; Serafini et al., 2004; Orlic et al., 1996; Relander et al.,
2002; von Laer et al., 1998; Kurre et al., 2001; Janssens et al.,
2003). The ability to redirect the binding of viral vectors to any
desired cell surface molecule, provided it is abundantly
expressed on the entire target cell population, would in theory
permit efficient transduction to be achieved for any type of
target cell (Sandrin et al., 2003). This approach would also
allow targeting of specific cell types in mixed populations
(Sandrin et al., 2003). The ability to target and efficiently
transduce specific subpopulations of cells within unfractionated
primary cell populations would be of importance for laboratory
experiments as well as for several types of gene therapy
applications. Direct infection of cell subpopulations would be
less labor-intensive and more cost-effective. In addition, it is
well recognized that manipulations involving purified cell
subpopulations often alter the functional properties of the cells.
Experiments and clinical protocols whereby specific subsets of
hematopoietic cells are purified prior to infusion would be
72 K. Morizono et al. / Virology 355 (2006) 71–81greatly simplified if specific cell types could be targeted directly
in non-fractionated populations.
Many attempts have been made to develop efficient and
generally useful targeting vectors. Most strategies are based
upon alteration of the retroviral envelope protein to modify its
binding specificity. Inserting peptides, ligands or single-chain
antibodies into the receptor-binding region of the envelope
protein is a common strategy (Martin et al., 2002; Jiang and
Dornburg, 1999; Han et al., 1995; Marin et al., 1996; Nilson et
al., 1996; Somia et al., 1995; Valsesia-Wittmann et al., 1994).
Bridging virus and cells with anchoring proteins is another way
to redirect the binding specificity of the virus (Boerger et al.,
1999; Roux et al., 1989). However, these approaches are not
generally applicable, due to low titers and/or poor specificity
(Kasahara et al., 1994; Zhao et al., 1999).
We developed a targeted oncoretroviral/lentiviral gene
transduction strategy by pseudotyping retroviral vectors with
a chimeric Sindbis virus envelope protein (Morizono et al.,
2001). Sindbis virus has two integral envelope proteins, E1 and
E2, and they form a trimer of the heterodimer. E2 mediates
binding to target cells, and E1 mediates fusion between the viral
envelope and the target cell membrane. A low pH environment
in the endosome elicits fusion activity of the E1 protein, which
then mediates fusion of the envelope to the endosome
membrane and penetration of virions into the cytoplasm
(Glomb-Reinmund and Kielian, 1998). We modified the native
Sindbis virus envelope protein by insertion of the Fc binding
region of protein A (ZZ domain) in the receptor-binding region.
The ZZ domain can bind the Fc region of monoclonal
antibodies; therefore, virus can be conjugated with specific
antibodies recognizing any desired cell surface molecule. We
demonstrated successful antibody-mediated targeting in vitro
within populations consisting of mixtures of cells bearing or not
bearing the target receptor. We further modified the ZZ
SINDBIS envelope protein to optimize targeting specificity
for in vitro and in vivo applications (Morizono et al., 2005).
Some types of hematopoietic cells are relatively resistant to
gene transduction by pseudotyped retroviral vectors, including
our targeting vectors. In some cases, cells are refractory to
transduction because of low expression levels of the receptor for
envelope proteins. For example, human hematopoietic stem
cells do not express high levels of Pit-1 and Pit-2, which are
receptors for GALV and amphotropic MLV envelope, respec-
tively, resulting in poor transduction efficiencies by vectors
pseudotyped with the GALV and the amphotropic MVL
envelopes (Orlic et al., 1996; Relander et al., 2002; von Laer
et al., 1998; Kurre et al., 2001). Human and murine primary B
lymphocytes are also relatively resistant to VSV-G-pseudotyped
vectors, due to low levels of expression of the VSV-G receptor
(Serafini et al., 2004; Unutmaz et al., 1999; Janssens et al.,
2003). In the case of our targeting vectors, the targeted cell
surface molecules, such as HLA, are abundantly expressed on
the cells, so blockage of gene transduction appears to occur after
binding, most likely at the fusion step.
The fusion activity of certain alphavirus envelope proteins
was previously shown to be activated by artificial acidification
of the virus. In one study, Semliki Forest Virus on target cellswas exposed to low-pH culture medium, resulting in artificial
fusion occurring at the surface of the infected cells (White et al.,
1980). In another study, Sindbis virus was incubated with
liposome, then exposed to acidic buffer, resulting in fusion
between the virus and the liposomes (Smit et al., 1999).
Therefore, we established conditions to enhance the effi-
ciency of transduction to primary cells in non-fractionated
populations. We combined our current targeting strategy with
artificial activation of fusion by transient low-pH treatment. This
new transduction method was examined for targeted gene
transduction of specific cell types, and we demonstrate efficient
transduction to cells currently refractory to oncoretoroviral/
lentiviral gene transduction, including primary hematopoietic
cells in non-purified bulk populations.
Results
Certain hematopoietic cell types are refractory to lentiviral
gene transduction
Infectivity of pseudotyped lentiviral vectors is restricted in
some hematopoietic cells. We constructed variants of the
previously described targeting envelope derived from the
Sindbis virus in order to enhance infectivity. Transduction
efficiency was tested using virus conjugated to anti-Human
leukocyte antigen (HLA) Class I antibodies. A mutation in the
E1 region was reported to mediate fusion in the absence of the
lipid cholesterol (Lu et al., 1999). Insertion of the mutation into
our targeting vector broadened the host range of the vector to
some hematopoietic cell types (data not shown). Another
mutation in the E2 region (m6) was found to increase the
infectivity of the targeting vector by an unknown mechanism
(Morizono et al., 2005). The envelope protein bearing these two
mutations, termed M6SGNUTR, enhanced infectivity 5- to 10-
fold for some hematopoietic cells over the parental targeting
envelope (ZZ SINDBIS (Morizono et al., 2001, 2005)) (Fig. 1a)
(data not shown). Although the vector transduced various types
of cells with higher efficiency, certain cell types remained
relatively refractory to transduction (Table 1). For example,
Jurkat and Raji cells were efficiently transduced using anti-HLA
antibody, whereas KG1a and MLCD34 cells were not (Table 1,
Fig. 1b).
Low pH treatment enhances infectivity of M6SGNUTR
pseudotypes
The target receptor HLA class I is abundantly expressed on
those refractory cell types (Fig. 1c). We also found that
M6SGNUTR pseudotypes efficiently bound to those cells when
they are conjugated with anti-HLA class I antibody (data not
shown). Therefore, we hypothesized that the block for
transduction was at a step in viral entry subsequent to binding
of virus to the target receptor. An earlier report for Semliki
Forest Virus and Sindbis virus demonstrated that reduction of
the pH in the culture medium following incubation of virus with
liposome or cells at 4 °C triggered fusion (White et al., 1980;
Smit et al., 1999). We tested whether treatment of the virus after
Fig. 1. MLCD34 cells are refractory to transduction by the M6SGNUTR-pseudotyped targeting vector. (a) Schematic representation of the mutations on M6SGNUTR.
The two integral membrane proteins E1 and E2 form heterodimers. E2 mediates binding to target cells. E1 mediates fusion between the viral envelope and the target
cell membrane. E3 and 6K work as signal sequence peptides for E2 and E1, respectively. The E2 KE159-160AA mutation enhanced titers of ZZ SINDBIS 1.2- to 2.5-
fold on all cell types, and the E1 AK226-227SG mutation enhanced titers of ZZ SINDBIS 5- to 20-fold on hematopoietic cells. (b) Jurkat and MLCD34 cells (5×104
cells each) were infected with the same amount (200 ng HIV p24) of cppt2e (VSV-G) or cppt2e (M6SGNUTR) with or without anti-HLA (5 μg/ml). EGFP expression
was analyzed by flow cytometry. (c) The cells were stained with anti-HLA class I (solid line) or isotype (mouse IgG2a) control antibody (dashed line) followed by
incubation with FITC-conjugated goat anti-mouse IgG.
73K. Morizono et al. / Virology 355 (2006) 71–81binding to the cell with low pH medium might enhance
infectivity of the M6SGNUTR lentiviral vector. The two
resistant cell lines showed a 20- to 25-fold enhancement of
infection when treated immediately following exposure to virus
with pH 5.0 buffer for 1 min (Table 1, Fig. 2a). EGFP






Raji Burkitt's lymphoma (B cell) 96
Jurkat Acute T-cell leukemia 83
KG1a Acute myelogenous leukemia 2
MLCD34 Immortalized CD34+ bone marrow cell 2
The same number of each type of cells (5×104) was infected with the same amount o
were then received low pH treatment (pH 5, 1 min, 20 °C). Three days post-infectiotranscriptase inhibitor, excluding the possibility of pseudo-
transduction by virion-associated EGFP protein (data not
shown). Additionally, EGFP expression was very low imme-
diately after transduction, reaching a maximal level at 3 days
post-infection, and was maintained for at least 7 days post-
infection (data not shown). Interestingly, pseudotypes with aEGFP+
V-G SINDBIS M6SGNUTR M6SGNUTR+
anti-HLA
+ − + − + − +
.50 88.56 <0.01 3.05 <0.01 2.12 63.45 73.00
.01 81.53 0.24 2.13 0.59 1.51 37.54 41.70
.43 1.45 <0.01 0.23 <0.01 0.43 0.20 4.22
.78 1.83 <0.01 0.07 <0.01 0.51 0.19 5.31
f each virus (20 ng of HIV p24 in 200 μl of medium). Some of the infected cells
n, EGFP expression was analyzed by flow cytometry.
Fig. 2. Low pH treatment of cells induces fusion activity of M6SGNUTR and enhances gene transduction by M6SGNUTR. (a) MLCD34 cells (5×104 cells each) were
incubated with the same amount (200 ng HIV p24) of cppt2e (VSV-G) or cppt2e (M6SGNUTR) with or without anti-HLA for 2 h. After infection, virus was removed,
then the cells were resuspended in citric acid buffer (pH 5) for 1 min at room temperature. The cells were washed after low pH treatment and cultured in normal culture
medium for 3 days. EGFP expression was analyzed by flow cytometry. (b) “Fusion from without” was observed on MLCD34 cells, which were infected with cppt2e
(M6SGNUTR) with anti-CD45 then exposed to citric acid buffer (pH 5). The photomicrograph was taken 10 min after removal of citric acid buffer and resuspension of
the cells in normal culture medium.
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dependent on low pH in the endosomes were not affected by
low pH treatment (Fig. 2a).
We chose two particularly refractory cell lines, KGIA and
MLCD34, for further investigation of enhanced transduction of
low pH (Fig. 2a). Incubation of the MLCD34 cells with the
M6SGNUTR vector sometimes caused aggregation of the cells
likely due to virus bridging of cells bearing the target receptor.
After the low pH treatment, the cells formed syncytia resulting
from fusion of aggregated cells (Fig. 2b). This observation is
consistent with activation of fusion between virus and cell bythe low pH treatment. Since “fusion from without” decreases the
viability of target cells, we seeded target cells on retronectin-
coated plates to prevent aggregation of cells. Target cells seeded
on retronectin-coated plates did not fuse after low pH treatment,
therefore, the cell viability was maintained.
Optimization of low-pH-mediated enhancement of transduction
We investigated the optimal conditions for the low pH
enhancement of infectivity. The maximal enhancement for
transduction of MLCD34 cells was observed between pH 4.5
75K. Morizono et al. / Virology 355 (2006) 71–81and pH 5.5 (Fig. 3a). Enhanced transduction did not occur when
using pseudotypes with envelopes derived from pH-dependent
VSV-G- or pH-independent RD114/TR in the range of pH
investigated (pH 4 to pH 6). Similar results were observed forFig. 3. Optimization of conditions for low-pH-mediated enhancement of transduction
HIV p24) of cppt2e (VSV-G), cppt2e (RD114/TR), cppt2e (M6SGNUTR), cppt2e (M
on retronectin-coated plates for 2 h. After infection, the virus was removed then the ce
temperature. EGFP expression was analyzed by flow cytometry 3 days post-infection
(M6SGNUTR) conjugated with either anti-HLA or anti-CD45. Infection and analy
MLCD34 cells were infected with cppt2e (M6SGNUTR) (200 ng HIV p24) conjuga
incubated with citric acid buffer (pH 5.5) for various durations at room temperature.
conjugated with anti-HLA. After infection, the viruses were removed then the cells w
MLCD34 cells were infected with various amounts (6, 20, 60 or 200 ng HIV p24) o
(M6SGNUTR) conjugated with anti-CD45. After infection, the virus was removed
temperature.another transduction refractory cell line KGIA (Fig. 3b). Since
no adverse effects on cells were observed at pH 5.5, this pH was
used for all the following experiments. Optimal time periods for
low pH treatment to obtain maximal transduction efficienciesbyM6SGNUTR. (a) MLCD34 cells were infected with the same amount (200 ng
6SGNUTR) with anti-HLA or cppt2e (M6SGNUTR) conjugated with anti-CD45
lls were incubated with citric acid buffer with various pH levels for 1 min at room
. (b) KG1a cells were infected with the same amount (200 ng HIV p24) of cppt2e
sis of EGFP expression were performed as described for MLCD34 cells. (c)
ted with anti-HLA. After infection, the virus was removed, then the cells were
(d) MLCD34 cells were infected with cppt2e (M6SGNUTR) (200 ng HIV p24)
ere incubated with citric acid buffer (pH 5.5) for 10 s at 4 °C, 20 °C or 37 °C. (e)
f cppt2e (VSV-G), cppt2e (M6SGNUTR) conjugated with anti-HLA or cppt2e
then the cells were incubated with citric acid buffer (pH 5.5) for 10 s at room
Fig. 4. Targeted gene transduction of specific populations of primary hematopoietic cells. (a) PHA-activated PBMC were infected with the same amount (200 ng HIV
p24 in 200 μl of medium) of cppt2e (VSV-G), cppt2e (M6SGNUTR), cppt2e (M6SGNUTR) conjugated with anti-HLA or cppt2e (M6SGNUTR) conjugated with
anti-CD4 on retronectin-coated plates for 2 h. After infection, cells received low pH treatment low pH and cultured in growth medium. Three days post-infection, cells
were stained with anti-CD4-PE and analyzed by flow cytometry. The percentages indicated in the upper and lower sides of the quadrant analysis are percentages of
EGFP-positive cells in the CD4-positive population and the CD4-negative population, respectively. Experiments are performed three times using cells from different
donors. Representative data are shown. (b) Analysis of forward, side scatter and B-cell marker (CD19 and CD20) expression of the bulk PBMC population used for B-
cell targeting. (c) PBMC were infected with same amount (200 ng HIV p24 in 200 μl of medium) of cppt2e (VSV-G), cppt2e (M6SGNUTR), cppt2e (M6SGNUTR)
conjugated with anti-CD19 or cppt2e (M6SGNUTR) conjugated with anti-CD20 on retronectin-coated plates for 2 h. After infection, cells received low pH treatment
and cultured in growth medium. Three days post-infection, cells were washed with acidic buffer to peal off the CD19 antibody used for infection. The cells were then
stained with anti-CD19-APC and analyzed by flow cytometry. CD19-negative and -positive populations were gated and analyzed individually to demonstrate
percentages of EGFP-positive cells in the CD19-negative and CD19-positive populations, respectively. Experiments are performed three times using cells from
different donors. Representative data are shown.
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Fig. 4 (continued).
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observed with a duration as short as 5 s. Shorter durations
were not feasible, given the technical manipulations involved.
These conditions of low pH treatment were consistent with
those for artificial fusion of alphaviruses with cells, which
occurred within a few seconds (White et al., 1980). Of note, low
pH treatment of the targeting virus before infection eliminated
infectivity (<0.2%) of the virus, indicating that the pH-induced
enhancement must occur after virus binding. Based upon these
results, cells were treated at pH 5.5 for 10 s for all subsequent
experiments. The same levels of transduction were observed at
temperatures of infection at 4 °C, 20 °C and 37 °C (Fig. 3d).
Therefore, low pH treatment was performed at pH 5.5 for 10 s at
room temperature. We also investigated whether the MOI of the
virus affected the transduction efficiency with low pH treatment(Fig. 3e). Regardless of MOI, enhancement of gene transduc-
tion with low pH treatment occurred efficiently, demonstrating
that this method is applicable for infecting any number of cells
and with any amount of virus.
Enhanced transduction to specific cells in unfractionated
primary cell populations
The primary advantage of the targeting vector is the ability to
infect specific cells within a population without the need for
physical purification of cell subpopulations. We next tested
targeted transduction of CD4+ T-cells in an unfractionated
population (Fig. 4a). Similar to the previously described results
with some cell lines, transduction of primary CD4+ T cells was
inefficient, even with antibody directed to the highly abundant
78 K. Morizono et al. / Virology 355 (2006) 71–81HLA class I molecule. Low pH treatment enhanced transduc-
tion efficiencies significantly (Fig. 4a). As expected, infection
targeted to HLA class I resulted in infection of both CD4+ and
CD4− populations. In contrast, infection with an anti-CD4
antibody followed by low pH treatment resulted in specific and
more efficient infection for the CD4+ population of the cells.
Thus, the use of specific targeting antibodies combined with
low pH treatment allows more effective targeted transduction of
specific primary lymphocyte populations in a non-fractionated
PBMC population.
Primary B cells are notoriously difficult to transduce by
VSV-G-pseudotyped lentiviral vectors (Serafini et al., 2004;
Unutmaz et al., 1999; Janssens et al., 2003). CD19+CD20+ B
cells comprise approximately 7% of total white blood cells
(Fig. 4b). VSV-G pseudotypes transduce only up to 6.6% of B
cells (CD19+ population) in a non-targeted fashion at the same
MOI used to transduce more than 50% of CD4+ cells (Fig.
4c). Without low pH treatment, transduction of bulk PBMC
populations with vector conjugated to either the anti-CD19 or
the CD20 antibody results in 4% and 15% targeted transduc-
tion of the CD19+ population, respectively. The CD20
targeting vector transduced B cells more efficiently than
VSV-G pseudotypes even without low pH treatment. Low pH
treatment further enhances transduction efficiency approxi-
mately 4-fold with anti-CD19 antibody and 1.3-fold with anti-
CD20. Thus, efficient and targeted transduction of primary B-
cell populations in non-fractionated peripheral blood cells can
be achieved by the targeting vector in combination with low
pH treatment.
Discussion
Our results demonstrate that transient treatment with low pH
culture medium immediately following infection by a lentiviral
targeting vector pseudotyped with a modified Sindbis virus
envelope can enhance infectivity 1.3- to greater than 40-fold
depending on the cell type. The treatment of cells with lowered
pH is a rapid and simple technique that is suitable for enhancing
transduction of multiple cell types. Most importantly, low pH
treatment can significantly enhance transduction efficiency to
primary cells and thereby enhances the utility of our strategy to
target specific cell types within non-fractionated hematopoietic
cell populations such as hematopoietic stem cells, T cells and
B cells.
The mechanism of action for the pH-induced enhancement
of transduction is likely related to the natural process of
Sindbis virus infection whereby endocytosis of the virus into
low pH endosomes results in fusion of the virus to the
endosomal membrane and entry of the viral capsid into the
cytoplasm. The extracellular change to low pH may mimic in
part the endosomal low pH eliciting conformational changes
that induce fusion with the endosome membranes (Edwards
et al., 1983; Paredes et al., 2004). Consistent with this
interpretation, treatment of free virions with low pH
abolished infectivity, indicating that pH-induced changes
leading to entry occur after virus binding to the target
receptor (Edwards et al., 1983). However, our studies alsoshow that the pH-induced changes are independent of the
native Sindbis virus receptor and can occur with multiple
target receptors recognized by specific antibodies. For wild
type Sindbis virus, other investigators reported that the
exposure to low pH was required to establish conditions for
membrane fusion but that fusion to the cell membrane did
not occur until return to neutral pH (Paredes et al., 2004). It
is also interesting to note that this low pH-induced
enhancement of infectivity is not true for all viruses (such
as VSV-G) that are pH-dependent for infection. One model
for the pH-induced enhancement is that the Sindbis envelope
undergoes a conformational change under low pH conditions,
allowing formation of contacts with as yet unidentified cell
surface molecules and that these interactions subsequently
lead to virus–cell fusion.
The ability to efficiently transduce and target specific cells in
unfractionated populations of primary cells could have several
applications in the laboratory or in clinical settings. Fractiona-
tion protocols can often be labor-intensive and expensive. In
addition, manipulations involved in purifying subpopulations of
cells may alter functional properties present in more natural
non-fractionated populations (Kay et al., 1983; Wang et al.,
2004; Koh et al., 2005; Simonelli et al., 1992). Multiple
experimental and clinical protocols exist whereby specific
subsets of CD34+ cells, T cells, B cells and/or dendritic cells are
purified prior to reinfusion (Zambidis et al., 1997; Severino et
al., 2003; Wendtner et al., 2004; Monahan and Salgaller, 1999;
Willemsen et al., 2003; Schmidt et al., 2003; Hacein-Bey-Abina
et al., 2002) for expression of therapeutic transgenes, immunor-
egulatory genes, cytokines and antigens. For example, chimeric
T-cell receptors recognizing tumor-associated antigens or viral
antigens have been introduced into purified CD8+ T cells to
elicit a cytotoxic immune response to cancer cells or virus-
infected cells (Hacein-Bey-Abina et al., 2002; Severino et al.,
2003). Purification of B cells and transduction ex vivo with
specific antigens has been utilized to induce tolerance to the
antigens (Zambidis et al., 1997). In each of these situations,
efficient targeted transduction in a bulk hematopoietic cell
population could facilitate the protocols and minimize the ex
vivo manipulations of cells that may potentially induce loss of
function and viability.
Insertional mutagenesis leading to the development of
malignant clones of transduced cells was observed as a serious
adverse effect in clinical trials involving the therapeutic
transduction of the common-γ chain transgene into X-linked
SCID patients (Hacein-Bey-Abina et al., 2003). In these
studies, the requirement for high multiplicities of infection
(MOI) required to achieve effective transduction could
increase retroviral integration events in cells expressing high
levels of viral receptor and thereby increase the probability of
insertional mutagenesis in those cells. The use of low pH
treatment and targeting receptors such as HLA that are
uniformly expressed at high levels in the population should
maximize the transgene expression while minimizing the risk
of insertional mutagenesis.
The relatively simple strategy of transient low pH treatment
of modified Sindbis targeting vectors brings us closer to the goal
79K. Morizono et al. / Virology 355 (2006) 71–81of achieving high efficiency transduction of any desired cell
type, particularly within non-fractionated populations of
primary cells. Greater understanding of the entry properties of




MLCD34 cells were obtained from Dr. Robert Donahue
(NHLBI, MA) and cultured in RPMI (Invitrogen, Carlsbad,
CA) with 20% fetal calf serum (FCS) and antibiotics (100U of
penicillin/ml and 100 μg of streptomycin/ml). Jurkat cells,
KG1a cells and Raji cells were cultured in RPMI with 10%
FCS and the antibiotics. MLCD34 is a line of immortalized
CD34-positive cells derived from cadaveric bone marrow
(Lawman et al., 1992). Peripheral blood mononuclear cells
(PBMC) were obtained, as previously described (Morizono,
Bristol, Xie, Kung, and Chen).
Plasmid
RD114/TR was provided by Dr. FranÇois-LoÏc Cosset
(Ecole Normale Superieure de Lyon, France) (Sandrin et al.,
2002). M6SGNUTR was constructed from the m6 mutant of
pIntron ZZ and the SGN mutant of TOTO1101 (provided by Dr.
Margaret Kielian, Albert Einstein College of Medicine)
(Morizono et al., 2001; Lu et al., 1999). Briefly, BsiW1–Xho1
fragment of the TOTO1101 (E1 region containing SGN
mutation) was substituted with the identical region of the m6
mutant of pIntron ZZ SINDBIS.
Virus production
All lentivirus vectors were produced by calcium-phos-
phate-mediated transient transfection of 293T cells, as
previously described (Morizono et al., 2001, 2005). Briefly,
293T cells (1.8×107 cells) were transfected with 12.5 μg of
pCMVR8.2DVPR, 12.5 μg of SIN18-RhMLV-E with central
polypurine tract (termed cppt2e) (Kung et al., 2005) and
optimized amounts (5 to 10 μg) of envelope-expressing
plasmids. The viral vectors were harvested in OptiMEM
(Invitrogen) with 2% FCS and antibiotics. To concentrate the
viral vector, the viruses were loaded onto Hanks balanced salt
solution (HBSS) with 10% (Wt/Wt) sucrose, 0.3% BSA and
1 mM EDTA. The virus was then ultracentrifuged at 20,000
RPI for 90 min at 4 °C by SW32 rotor (Beckman, Palo Alto,
CA). The pellets were resuspended in a 100-fold lower
volume of HBSS.
Virus infection of cell lines
Jurkat (5×104 cells) and CD34ML cells (5×104 cells) were
infected with the same amount (200 ng of HIV p24) of cppt2e
(VSV-G), cppt2e (RD114/TR), cppt2e (M6SGNUTR), cppt2e
(M6SGNUTR) conjugated with anti-HLA class I (5 μg/ml)(Sigma, St. Louis, MO) or cppt2e (M6SGNUTR) conjugated
with anti-CD45 (5 μg/ml) (ATCC). Cells were incubated in
1.5-ml tubes at 37 °C for 2 h. After the viruses were rinsed,
some of the infected cells were treated with citric acid buffer
(0.131 M citric acid, 0.066 M Na2HPO4, pH 5) for 1 min at
room temperature. The buffer was then changed to culture
medium. Three days post-infection, EGFP expression was
analyzed by flow cytometry. To test patterns of infectivity of
each of the pseudotypes, various cells types (Raji, Jurkat, KG1a
and MLCD34) were infected with different pseudotypes with or
without low pH treatment. The same number of cells (5×104)
were infected with the same amount of each virus (20 ng of HIV
p24 in 200 μl of medium). Some of the infected cells then
received low pH treatment (pH 5, 1 min, 20 °C). Three days
post-infection, EGFP expression was analyzed by flow
cytometry. After the first finding of low-pH-mediated enhance-
ment of transduction, infections were performed using retro-
nectin-coated 24-well plates (Takara Bio Inc, Japan). To
determine the optimal range of pH for transduction, cells
(5×104) infected with viruses (200 ng of HIV p24) were treated
with citric acid buffer of various pH levels for 1 min at room
temperature; to determine the optimal duration of low pH
treatment, cells (5×104) infected with viruses (200 ng of HIV
p24) were treated with citric acid buffer (pH 5.5) for various
durations at room temperature; to determine the optimal
temperature for low pH treatment, cells (5×104) infected with
viruses (200 ng of HIV p24) were treated with citric acid buffer
(pH 5.5) for 10 s at various temperatures; to determine the effect
of MOI on transduction, cells (5×104) were infected with
various amounts of virus (6, 20, 60 or 200 ng of HIV p24) then
treated with citric acid buffer pH 5.5 levels for 10 s at room
temperature.
Flow cytometry for HLA class I
The same number of cells (5×105) were incubated with anti-
HLA class I (Sigma) or isotype (mouse IgG2a) control antibody
(eBioscience, San Diego, CA) (5 μg/ml) for 30 min at 4 °C
followed by incubation with FITC-conjugated goat anti-mouse
IgG (1:200) (Cappel, Durham, NC) for 30 min at 4 °C and
analyzed by flow cytometry.
Virus infection of primary cells
For T-cell targeting, PBMC were cultured in T-cell growth
medium [RPMI with 10% FCS, IL-2 (10 U/ml) and antibiotics]
with phytohemaglutinin (25 μg/m) for 2 days. The cells were
seeded in 24-well retronectin-coated plates (1×106 cells/ml)
1 day prior to infection. Cells were infected with the same
amount (200 ng of HIV p24 in 200 μl of OptiMEM) of cppt2e
(VSV-G), cppt2e (M6SGNUTR), cppt2e (M6SGNUTR) con-
jugated with anti-HLA class I (5 μg/ml) or cppt2e
(M6SGNUTR) conjugated with anti-CD4 antibody (OKT4)
(5 μg/ml) (ATCC) for 2 h at 37 °C. After infection, 200 μl of
citric acid buffer (pH 5) was added to some of the infected wells
for 10 s. Viruses were then removed from wells, and cells were
cultured in T-cell growth medium for 3 days. The PBMC were
80 K. Morizono et al. / Virology 355 (2006) 71–81stained with 100 μl of anti-CD4-PE (5 μg/ml) (BD Bioscience,
San Diego, CA) for 30 min on ice. The cells were then washed
with FACS buffer and analyzed by flow cytomery. For B-cell
targeting, PBMC were cultured in B-cell growth medium
[RPMI with 10% FCS, IL-2 (10 U/ml), 2-mercaptoethanol
(50 μM), IL-4 (10 ng/ml), soluble CD40 ligand (250 μg/ml) and
antibiotics] for 1 day. The cells are seeded in 24-well
retronectin-coated plates (1×106 cells/ml) 1 day prior to
infection. Cells were infected with the same amount (200 ng
of HIV p24 in 200 μl of OptiMEM) of cppt2e (VSV-G), cppt2e
(M6SGNUTR), cppt2e (M6SGNUTR) conjugated with anti-
CD19 (5 μg/ml) (eBioscience) or cppt2e (M6SGNUTR)
conjugated with anti-CD20 antibody (5 μg/ml) (ATCC) for
2 h at 37 °C. After the infection, 200 μl of citric acid buffer
(pH 5) was added to some of the infected wells for 10 s.
Viruses were then removed from wells, and cells were cultured
in B-cell growth medium for 3 days. The PBMC were washed
once with citric acid buffer (pH 3.3) then stained with 100 μl
of anti-CD19-APC (5 μg/ml) (eBioscience) for 30 min on ice.
The cells were analyzed by flow cytometry.
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